Prospective Registry on User Experience With The Mapping System For Ablation Procedures

NCT ID: NCT02698670

Last Updated: 2018-01-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

577 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-25

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, prospective, non-randomized, multicenter, post approval study being conducted in the United States, Europe and Asia-Pacific Regions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TRUE HD Study is aimed at collecting real-world data on the use of the Rhythmia mapping system and the IntellaMap Orion mapping catheter in patients indicated for ablation procedure with use of a 3D Mapping system.

The study will collect specific information on management of ablation procedures with the commercial system including but not limited to acute procedural success, type and proportion of arrhythmias mapped/treated, and how mapping system is used overall. Usage data may be used for the planning of future clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrhythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rhythmia mapping system

A 3-D Cardiac Mapping system

Intervention Type DEVICE

IntellaMap Orion mapping catheter

A diagnostic basket mapping catheter

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who are eligible for an ablation procedure with the Rhythmia 3D mapping system and IntellaMap Orion mapping catheter according to current international and local guidelines (and future revisions) and per physician discretion;
* Subjects who are willing and capable of providing informed consent;
* Subjects who are willing and capable of participating in all testing associated with this clinical investigation at an approved clinical investigational center;
* Subjects whose age is 20 years or above, or of legal age to give informed consent specific to state and national law.

Exclusion Criteria

* Subjects requiring de novo ablation of atrial fibrillation;
* Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility\*;
* The subject is unable or not willing to complete follow-up visits and examination for the duration of the study;
* Subjects who have undergone a previous cardiac ablation within 30 days prior to enrollment;
* Unrecovered/unresolved Adverse Events from any previous invasive procedure;
* Women of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Scientific Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerhard Hindricks

Role: PRINCIPAL_INVESTIGATOR

Gerhard Hindricks

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Hoag Memorial Hospital

Orange, California, United States

Site Status

Torrance Memorial Medical Center

Torrance, California, United States

Site Status

University of Chicago Hospital

Chicago, Illinois, United States

Site Status

University of Kansas Hospital

Kansas City, Kansas, United States

Site Status

University of Michigan Hospitals

Ann Arbor, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Nebraska Heart Institute

Lincoln, Nebraska, United States

Site Status

Maimonidies Hospital

New York, New York, United States

Site Status

Strong Memorial Hospital of the University of Rochester

Rochester, New York, United States

Site Status

University of North Carolina Hospital

Chapel Hill, North Carolina, United States

Site Status

Riverside Methodist - Ohio Health

Cincinnati, Ohio, United States

Site Status

Good Samaritan Hospital

Cincinnati, Ohio, United States

Site Status

Heart Rhythm Institute

Oklahoma City, Oklahoma, United States

Site Status

Oregon Health Sciences University

Portland, Oregon, United States

Site Status

Baptist Memorial Hosptial

Memphis, Tennessee, United States

Site Status

Trinity Mother Francis

Tyler, Texas, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

Wesley Medical Research

Brisbane, Queensland, Australia

Site Status

CHU de Bordeaux

Pessac, , France

Site Status

Centre Hôpital Universitaire Rangueil

Toulouse, , France

Site Status

Universitaetsklinik Eppendorf

Hamburg, , Germany

Site Status

Herzzentrum Universität Leipzig

Leipzig, , Germany

Site Status

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Clinica Universitaria de Navarra

Pamplona, , Spain

Site Status

Harefield Hospital

London, , United Kingdom

Site Status

The Brompton Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia France Germany Hong Kong Netherlands Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

91118280

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vis-Rx Prime Micro-Imaging Catheter Study
NCT06685783 ACTIVE_NOT_RECRUITING
Autoimmune Basis for Postural Tachycardia Syndrome
NCT02725060 ENROLLING_BY_INVITATION NA
POTS Stroke Volume
NCT05796154 NOT_YET_RECRUITING NA
Vis-Rx Post-Market Evaluation
NCT04533503 COMPLETED